Skip to content
Resolve Therapeutics, LLC.
Resolve Therapeutics, LLC.Resolve Therapeutics, LLC.
  • About Us
    • Our Company
    • Management Team
    • Contact Us
  • Product Candidates
    • Our Pipeline
    • RSLV-132
    • RSLV-145
    • RSLV-621
  • Science
    • Nuclease Therapy Platform
    • Publications
  • Unmet Medical Need
    • Sjögren’s syndrome
    • Lupus
    • Patient Resources & Advocacy
  • News
  • About Us
    • Our Company
    • Management Team
    • Contact Us
  • Product Candidates
    • Our Pipeline
    • RSLV-132
    • RSLV-145
    • RSLV-621
  • Science
    • Nuclease Therapy Platform
    • Publications
  • Unmet Medical Need
    • Sjögren’s syndrome
    • Lupus
    • Patient Resources & Advocacy
  • News

Daily Archives: June 13, 2019

Resolve Therapeutics Announces RSLV-132 Significantly Reduces Fatigue in Phase II Study of Patients with Sjögren’s Syndrome

NewsBy James PosadaJune 13, 2019

Resolve Therapeutics Announces RSLV-132 Significantly Reduces Fatigue in Phase II Study of Patients with Sjögren’s Syndrome

© 2020 Resolve Therapeutics. All rights reserved.

Sitemap   Terms of Use   Privacy Policy  

Go to Top